Evotec signs novel antibiotics research deal with Nosopharm

By Melissa Fassbender

- Last updated on GMT

(Images: Getty/Pinkypills)
(Images: Getty/Pinkypills)

Related tags Evotec Antibiotics Drug discovery First-in-human Clinical trials

Evotec is collaborating with Nosopharm, which expects to launch first-in-human studies in 2021, to accelerate the development of novel antibiotics.

Founded in 2009 and based in Lyon, France, Nosopharm is researching and developing new anti-infective drugs. The company has a staff of seven and to date has raised a total of €4.3m ($5.2m) in private equity in addition to €3.8m ($4.6m) in grants.

The drug discovery and development company Evotec recently announced a partnership with the French company, through which it will advance Nosopharm’s lead candidate, NOSO-502.

The initial focus of the agreement – financial terms of which were not disclosed – is on chemistry, manufacturing and control (CMC) and other clinical trial application-enabling activities for NOSO-502, for which first-in-human studies are expected in 2021.

The Phase I clinical trial will evaluate the use of NOSO-502 in the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Evotec also will work to develop a second-generation Odilorhabdin drug candidate. According to the company, the clinical candidate selection process for NOSO-2G is expected in 2022.

Dr. Cord Dohrmann, chief scientific officer at Evotec, said in a statement: “We are thrilled to play a key role in this partnership and we believe that with the unique combination of our infectious disease expertise and drug discovery and early development platforms, the lead candidates will soon enter the clinic and bring hope to physicians and their patients living with nosocomial infections caused by multidrug-resistant bacteria.”

In June 2018, Evotec signed a deal to integrate Sanofi’s infectious disease unit​ into its organization and license-in the majority of the Sanofi’s infectious disease research portfolio and initiatives.

The transaction more than doubled the number of scientists employed at Evotec, as 100 Sanofi employees were integrated into its global drug discovery and development operations.

Related news

Show more

Related products

show more

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Validate clinical study data with Formedix CORE

Validate clinical study data with Formedix CORE

Content provided by Formedix | 19-Jun-2023 | White Paper

In April 2023 at the CDISC Europe Interchange, we launched Formedix CORE, the first free-to-use, downloadable application encompassing the CDISC Open Rules...

Related suppliers

Follow us


View more